Correlation Between Ingen Technologies and Lifeline Biotechnologies

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Ingen Technologies and Lifeline Biotechnologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ingen Technologies and Lifeline Biotechnologies into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ingen Technologies and Lifeline Biotechnologies, you can compare the effects of market volatilities on Ingen Technologies and Lifeline Biotechnologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ingen Technologies with a short position of Lifeline Biotechnologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ingen Technologies and Lifeline Biotechnologies.

Diversification Opportunities for Ingen Technologies and Lifeline Biotechnologies

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Ingen and Lifeline is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Ingen Technologies and Lifeline Biotechnologies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lifeline Biotechnologies and Ingen Technologies is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ingen Technologies are associated (or correlated) with Lifeline Biotechnologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lifeline Biotechnologies has no effect on the direction of Ingen Technologies i.e., Ingen Technologies and Lifeline Biotechnologies go up and down completely randomly.

Pair Corralation between Ingen Technologies and Lifeline Biotechnologies

Given the investment horizon of 90 days Ingen Technologies is expected to generate 2.21 times less return on investment than Lifeline Biotechnologies. But when comparing it to its historical volatility, Ingen Technologies is 1.17 times less risky than Lifeline Biotechnologies. It trades about 0.09 of its potential returns per unit of risk. Lifeline Biotechnologies is currently generating about 0.18 of returns per unit of risk over similar time horizon. If you would invest  0.00  in Lifeline Biotechnologies on October 12, 2024 and sell it today you would earn a total of  0.02  from holding Lifeline Biotechnologies or generate 9.223372036854776E16% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy94.09%
ValuesDaily Returns

Ingen Technologies  vs.  Lifeline Biotechnologies

 Performance 
       Timeline  
Ingen Technologies 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Ingen Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Ingen Technologies is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.
Lifeline Biotechnologies 

Risk-Adjusted Performance

16 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Lifeline Biotechnologies are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady fundamental drivers, Lifeline Biotechnologies displayed solid returns over the last few months and may actually be approaching a breakup point.

Ingen Technologies and Lifeline Biotechnologies Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Ingen Technologies and Lifeline Biotechnologies

The main advantage of trading using opposite Ingen Technologies and Lifeline Biotechnologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ingen Technologies position performs unexpectedly, Lifeline Biotechnologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifeline Biotechnologies will offset losses from the drop in Lifeline Biotechnologies' long position.
The idea behind Ingen Technologies and Lifeline Biotechnologies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Complementary Tools

Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Fundamental Analysis
View fundamental data based on most recent published financial statements